Bradley C S, Bullinger M, McCusker P J, Wakefield C D, Blanchette V S, Young N L
Department of Rehabilitation Services, The Hospital for Sick Children, Toronto, ON, Canada.
Haemophilia. 2006 Nov;12(6):643-53. doi: 10.1111/j.1365-2516.2006.01346.x.
Disease-specific measures of quality of life (QoL) for children with haemophilia are now available for use in clinical studies [Haemophilia, 10, 2004, 9-16]. One of these measures, the Canadian Haemophilia Outcomes - Kids' Life Assessment Tool (CHO-KLAT), was developed in Canada with emphasis on the perspectives of children [Pediatr Blood Cancer, 47, 2006, 305-11; Haemophilia, 10, 2004, 34-43]. Another, the Haemo-QoL, was developed in Europe, with emphasis on the perspectives of clinicians [Haemophilia, 8, 2002, 47-54; Haemophilia, 10, 2004, 17-25]. While these two measures are unique and independent, researchers from both studies were collaboratively linked throughout development and testing. This study presents the results of a joint assessment of the two measures with respect to their strengths, limitations and unique contributions. The primary questions addressed were: 1 What is the relationship between the CHO-KLAT and the Haemo-QoL in terms of summary scores and item content? 2 What are the methodological strengths, limitations and unique contributions of each measure? We conducted a retrospective analysis of data from field testing of both measures. The analysis included a comparative assessment of the basic validity, reliability and items used in each measure. Overall, the CHO-KLAT and the Haemo-QoL are promising and valuable measures of QoL for children with haemophilia. Our analyses confirmed the basic psychometric properties of both tools, but identified some discrepancies between them. Additional data will allow for greater understanding of these discrepancies and lend clarity to how the tools should be used in clinical studies (separately or merged). The present recommendation is that the measures be run independently, but preferably concurrently in studies of children with haemophilia.
针对血友病患儿的特定疾病生活质量(QoL)测量方法现已可用于临床研究[《血友病》,第10卷,2004年,第9 - 16页]。其中一种测量方法,即加拿大血友病结局 - 儿童生活评估工具(CHO - KLAT),是在加拿大开发的,重点关注儿童的观点[《儿科血液肿瘤学》,第47卷,2006年,第305 - 311页;《血友病》,第10卷,2004年,第34 - 43页]。另一种是欧洲开发的血友病生活质量量表(Haemo - QoL),重点关注临床医生的观点[《血友病》,第8卷,2002年,第47 - 54页;《血友病》,第10卷,2004年,第17 - 25页]。虽然这两种测量方法是独特且独立的,但两项研究的研究人员在整个开发和测试过程中进行了合作。本研究展示了对这两种测量方法在优势、局限性和独特贡献方面进行联合评估的结果。所解决的主要问题是:1. 就总分和项目内容而言,CHO - KLAT与Haemo - QoL之间的关系是什么?2. 每种测量方法在方法学上的优势、局限性和独特贡献是什么?我们对两种测量方法现场测试的数据进行了回顾性分析。该分析包括对每种测量方法的基本效度、信度和所使用项目的比较评估。总体而言,CHO - KLAT和Haemo - QoL是用于评估血友病患儿生活质量的有前景且有价值的测量方法。我们的分析证实了这两种工具的基本心理测量特性,但也发现了它们之间的一些差异。更多数据将有助于更深入地理解这些差异,并明确这些工具在临床研究中应如何使用(单独使用还是合并使用)。目前的建议是,在血友病患儿的研究中,这些测量方法应独立进行,但最好同时进行。